Purpose statement: The purpose of this project was to improve provider knowledge of perinatal mood and anxiety disorders (PMADs) and the Edinburgh Postnatal Depression Scale (EPDS) and ultimately to nurture the family environment though identification and referral of positive EPDS screens. Background: Postpartum depression (PPD) affects 14% of mothers and 10% of fathers (Wisner et al., 2013). The United States Preventative Services Task Force (USPSTF) (2019) reviewed questionnaires to help identify PMADs. The EPDS was identified as the preferred method for identifying the risk of PMADs when using a single screening tool, and the Patient Health Questionnaire-2 (PHQ-2) as an inadequate screening tool. Additionally, the American Academy of Pediatrics (AAP) recommends using the EPDS to monitor a caregiver’s risk for PMADs (Rafferty et al, 2019). The local clinic’s standard of practice for screening a caregiver’s mental health was using the PHQ-2 at well child visits. Methods: The Model for Quality Improvement (Langley et al., 2009) provided the framework for the project allowing for changes to occur using the Plan-Do-Study-Act cycle. Clinicians and nursing staff attended an educational in-service on PMADs, EPDS, documentation options, and local resources. Following USPSTF and AAP recommendations, and support from five key stakeholders, the EHR documentation and papers were modified to remove the PHQ-2 from the 2-, 4-, 6-, and 9-month well-child templates and replaced with the EPDS. Findings: Provider knowledge was measured using a pre and post implementation six question, 5-point Likert scale survey. Provider knowledge of PMADs and EPDS screening practices increased by 90% from pre-implementation. The EPDS screening was completed at 95% of the visits. Of the patients having an EPDS score ≥10 EPDS, 19% were provided options for local therapists, prescribers. Discussion: Provider and staff education on PMADs and the EPDS improved adoption of properly screening and supporting families. Integration of the EPDS into the EHR resulted in clinically significant higher screen rates compared to the use of the PHQ-2.